Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of BKM120 in Relapsed and Refractory NHL

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient had a histologically confirmed diagnosis of mantle cell lymphoma, follicular lymphoma, or diffuse large B cell lymphoma.~2. Patient had relapsed or refractory disease and received at least one prior therapy.~3. Patient with diffuse large B cell lymphoma had received or was ineligible for autologous or allogeneic stem cell transplant.~4. Patient had at least one measurable nodal lesion (≥2 cm) according to Cheson criteria (Cheson 2007). In case where the patient had no measurable nodal lesions ≥ 2 cm in the long axis at baseline, then the patient must have had at least one measurable extra-nodal lesion.~5. Patient had an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.~6. Patient had adequate bone marrow and organ function.~Exclusion Criteria:~1. Patient had received previous treatment with PI3K inhibitors~2. Patient had evidence of graft versus host disease (GVHD).~3. Patient had active or history of central nervous system (CNS) disease.~4. Patient had a concurrent malignancy or had a malignancy within 3 years of study enrollment (with the exception of adequately treated basal or squamous cell carcinoma or non-melanomatous skin cancer).~5. Patient had a score ≥ 12 on the PHQ-9 questionnaire.~6. Patient had a GAD-7 mood scale score ≥ 15.~7. Pregnant or nursing women~8. Patient who did not use highly effective contraception methods to avoid becoming pregnant or conceiving offspring.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DLBCL Cohort (Type: EXPERIMENTAL): Diffuse large B-cell lymphoma cohort
- MCL Cohort (Type: EXPERIMENTAL): Mantle cell lymphoma cohort
- FL Cohort (Type: EXPERIMENTAL): Follicular lymphoma cohort

Based on this trial design, predict the completion outcome and termination type (if applicable).